Kymera Therapeutics, Inc. — Director's Dealing 2021

Mar 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kymera Therapeutics, Inc. (KYMR)
CIK: 0001815442
Period of Report: 2021-03-01

Reporting Person: Mainolfi Nello (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-01	Stock Option (Right to Buy)	$48.46	A	375000	Acquired	2031-02-28	Common Stock (375000)	Direct

Footnotes

F1: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments over three (3) years following the Grant Date, with the first installment vesting on April 1, 2021.